GlassScriptPhysician profile
Kathryn Ann Hartman
NPI 1073605929
$1,845.48
in general payments reported to CMS, 2019-2025
25 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $174 · 2021: $281 · 2022: $288 · 2023: $422 · 2024: $325 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $206.85 | 2019-2025 | Pediarix, Bexsero, Rotarix |
| Cranial Technologies, INC | $191.39 | 2019-2025 | Doc Band |
| Supernus Pharmaceuticals, INC. | $190.99 | 2021-2025 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $176.31 | 2019-2024 | Vaxneuvance, Gardasil 9, Proquad |
| Corium, LLC | $156.28 | 2022-2024 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $136.63 | 2021-2024 | Flumist Quadrivalent |
| Sobi, INC | $126.83 | 2020-2023 | |
| Kaleo, INC. | $73.90 | 2019-2024 | Auvi-Q |
| Tris Pharma INC | $72.01 | 2020-2023 | Dyanavel Xr |
| Pfizer INC. | $60.47 | 2023-2024 | |
| Sanofi Pasteur INC. | $56.29 | 2021-2024 | |
| Adlon Therapeutics L.P. | $52.50 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $52.20 | 2024-2025 | |
| Seqirus USA INC | $46.09 | 2025 | Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $45.27 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $39.90 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $24.37 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.80 | 2021 | |
| Biomarin Pharmaceutical INC. | $23.27 | 2022 | |
| Abbott Laboratories | $17.04 | 2019 | |
| Neurelis, INC. | $16.51 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.98 | 2024 | Zoryve |
| Ultragenyx Pharmaceutical INC. | $15.73 | 2022 | |
| Genentech USA, INC. | $13.76 | 2020 | |
| Mylan Pharmaceuticals INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Hartman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.